About Plexxikon
Plexxikon is a company based in Berkeley (United States) founded in 2000 was acquired by Daiichi Sankyo in February 2011. Plexxikon has raised $72.86 million across 2 funding rounds from investors including Daiichi Sankyo, Gimv and Pappas Capital. Plexxikon offers products and services including Zelboraf and Turalio. Plexxikon operates in a competitive market with competitors including Merck, AbbVie, Lilly, Roche and Novo Nordisk, among others.
- Headquarter Berkeley, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Plexxikon Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$72.86 M (USD)
in 2 rounds
-
Latest Funding Round
$46 M (USD), Series B
May 26, 2004
-
Investors
Daiichi Sankyo
& 7 more
-
Employee Count
Not available
-
Acquired by
Daiichi Sankyo
(Feb 28, 2011)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Plexxikon
Plexxikon offers a comprehensive portfolio of products and services, including Zelboraf and Turalio.
A drug invented for personalized medicine treatments.
Another drug developed for personalized medicines.
People of Plexxikon
Unlock access to complete
Leadership Team
1 people
Secretary Team
1 people
Assistant Team
1 people
Treasurer Team
1 people
Unlock access to complete
Funding Insights of Plexxikon
Plexxikon has successfully raised a total of $72.86M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $46 million completed in May 2004. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Plexxikon
Plexxikon has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Daiichi Sankyo, Gimv and Pappas Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VC firm focusing on life science sector
|
Locked | Locked | Locked | |
|
VC firm making investment in early stage startups in the US
|
Locked | Locked | Locked | |
|
Venture capital firm focused on healthcare companies
|
Locked | Locked | Locked |
Investor details for Plexxikon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Plexxikon
Investment portfolio details for Plexxikon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Plexxikon
Detailed financials for Plexxikon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Plexxikon Comparisons
Peer comparison for Plexxikon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Plexxikon
Plexxikon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, AbbVie, Lilly, Roche and Novo Nordisk, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Pharmaceuticals and diagnostics kits are developed for various diseases.
|
|
| Locked | Locked | Locked |
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
Detailed competitors of Plexxikon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Plexxikon
Complete news archive for Plexxikon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Plexxikon
Plexxikon was founded in 2000 and raised its 1st funding round 2 years after it was founded.
Plexxikon is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Plexxikon is a funded company, having raised a total of $72.86M across 2 funding rounds to date.
Founded in 2000 in Berkeley, United States, Plexxikon operates in the pharmaceutical sector, focusing on small molecule drugs for oncology, central nervous system disorders, and autoimmune conditions. A proprietary Scaffold-Based Drug Discovery Platform is utilized to create selective therapies. ZELBORAF (vemurafenib), discovered in 2005, was co-developed with Roche and approved in over 40 countries, accompanied by a diagnostic tool. The company was acquired by Daiichi Sankyo in 2011.
Plexxikon's top competitors include Merck, Roivant Sciences and Amgen.
Plexxikon offers Zelboraf and Turalio.
Plexxikon has 8 investors. Key investors include Daiichi Sankyo, Gimv, Pappas Capital, Advanced Technology Ventures, and Alta Partners.